2024
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian age
2021
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis
Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. European Heart Journal 2021, 43: 300-312. PMID: 34791123, PMCID: PMC8914878, DOI: 10.1093/eurheartj/ehab745.Peer-Reviewed Original ResearchConceptsNew-onset atrial fibrillationBreast cancer patientsBreast cancer diagnosisAtrial fibrillationCancer patientsBreast cancer stageRisk factorsBreast cancerCardiovascular mortalityCancer stageCancer diagnosisAF incidenceBreast cancer-related mortalityDevelopment of AFCox proportional hazards modelNew primary diagnosisOnset atrial fibrillationRisk survival statisticsSEER-Medicare analysisCardiovascular risk factorsEnd Results-MedicarePrevalent atrial fibrillationKaplan-Meier methodUnited States cohortCancer-related mortalitySurvival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.
Grimm M, Ramaswamy B, Lustberg M, Wesolowski R, Sardesai S, VanDeusen J, Cherian M, Stover D, Gatti-Mays M, Pariser A, Kassem M, Stephens J, Palettas M, Williams N. Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study. Journal Of Clinical Oncology 2021, 39: e13056-e13056. DOI: 10.1200/jco.2021.39.15_suppl.e13056.Peer-Reviewed Original ResearchFirst-line endocrine therapyProgression-free survivalInvasive lobular carcinomaMedian progression-free survivalEndocrine therapyMedian overall survivalOverall survivalBreast cancerDuctal cancerLobular cancerEstrogen receptor/progesterone receptorMetastatic invasive lobular carcinomaOhio State University Comprehensive Cancer CenterDistinct clinicopathologic characteristicsInitial endocrine therapyInitiation of chemotherapyYear of diagnosisKaplan-Meier methodMetastatic breast cancerSite of metastasisInvasive breast cancerSingle-institution studyComprehensive cancer centerLine endocrine therapyConcerns of resistance
2019
LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY
Williams N, Rinehardt H, Morgan E, Kassem M, Palettas M, Puduvalli V, Giglo P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY. Neuro-Oncology Advances 2019, 1: i8-i8. PMCID: PMC7213376, DOI: 10.1093/noajnl/vdz014.033.Peer-Reviewed Original ResearchDiagnosis of LCMagnetic resonance imagingLeptomeningeal carcinomatosisLMC diagnosisOverall survivalPrimary cancerOhio State University Comprehensive Cancer CenterSingle-institution retrospective studyCentral nervous system malignanciesMedian overall survivalStage II diseaseStage III diseaseStage IV diseaseKaplan-Meier methodPrimary breast cancerSurvival of patientsNervous system malignanciesCerebrospinal fluid cytologySolid tumor malignanciesConfirmation of diagnosisComprehensive cancer centerClinical characteristicsMedian ageMRI findingsInitial diagnosisSurvival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.
Sardesai S, Kassem M, Morgan E, Palettas M, Stephens J, Williams N, Stover D, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B. Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer. Journal Of Clinical Oncology 2019, 37: e12050-e12050. DOI: 10.1200/jco.2019.37.15_suppl.e12050.Peer-Reviewed Original ResearchDisease-free survivalPositive breast cancerHormone receptor expressionOverall survivalBreast cancerReceptor expressionPositive diseaseTumor gradeEarly-stage HER2-positive breast cancerOhio State University Comprehensive Cancer CenterSecond primary breast cancerSingle-institution retrospective analysisHER2-positive breast cancerAdjuvant ovarian suppressionHR-negative diseaseHR-negative patientsHR-positive diseaseTriple-positive diseaseAnti-estrogen therapyComplete pathologic responseSingle institution experienceKaplan-Meier methodPrimary breast cancerInvasive ductal cancerLow tumor gradeAssessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University.
Rinehardt H, Morgan E, Kassem M, Palettas M, Miah A, Alnahhas I, Guillermo Prieto Eibl P, Suresh A, Ganju A, Williams N, Puduvalli V, Giglio P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University. Journal Of Clinical Oncology 2019, 37: e13554-e13554. DOI: 10.1200/jco.2019.37.15_suppl.e13554.Peer-Reviewed Original ResearchDiagnosis of LCMagnetic resonance imagingLeptomeningeal carcinomatosisLMC diagnosisOverall survivalMRI findingsPrimary cancerLung cancerBreast cancerOhio State University Comprehensive Cancer CenterStage IV breast cancerSingle-institution retrospective studyCentral nervous system malignanciesMedian overall survivalStage II diseaseStage III diseaseStage IV diseaseHigh-risk patientsKaplan-Meier methodPrimary breast cancerSurvival of patientsNervous system malignanciesCerebrospinal fluid cytologyConfirmation of diagnosisComprehensive cancer centerCLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience
Boutrid H, Lustberg M, Vandeusen J, Sardesai S, Stover D, Wesolowski R, Cherian M, Stephens J, Palettas M, Morgan E, Kassem M, Berger M, Vargo C, Ramaswamy B, Williams N. CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience. Journal Of The National Comprehensive Cancer Network 2019, 17: clo19-027. DOI: 10.6004/jnccn.2018.7251.Peer-Reviewed Original ResearchMetastatic invasive lobular carcinomaProgression-free survivalInvasive lobular carcinomaFirst-line treatment groupEndocrine therapyFirst-line treatmentOverall survivalCDK 4/6 inhibitorsMetastatic settingBone metastasesTreatment groupsMedian progression-free survivalOhio State University Comprehensive Cancer CenterInvasive breast cancer casesOnly bone metastasesMedian overall survivalFirst-line therapyWidespread metastatic diseaseKaplan-Meier methodRetrospective chart reviewSingle institution experienceInvasive ductal cancerKaplan-Meier curvesPreferred treatment optionAppropriate clinical context